Shimizu, Yuki
Okada, Koutaroh
Adachi, Jun http://orcid.org/0000-0003-1220-3246
Abe, Yuichi
Narumi, Ryohei
Uchibori, Ken http://orcid.org/0000-0003-1491-923X
Yanagitani, Noriko
Koike, Sumie
Takagi, Satoshi http://orcid.org/0000-0001-9749-1034
Nishio, Makoto
Fujita, Naoya http://orcid.org/0000-0002-9631-9264
Katayama, Ryohei http://orcid.org/0000-0001-7394-895X
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP19H03524, JP20K21554, JP17H06327)
Japan Agency for Medical Research and Development (JP21cm0106203h0006, JP21ck0106472h0003)
Nippon Foundation (N/A)
Article History
Received: 4 September 2021
Accepted: 11 February 2022
First Online: 17 March 2022
Competing interests
: M. Nishio received grants and personal fees Ono Pharmaceutical, grants, Bristol Myers Squibb, Pfizer, Chugai Pharmaceutical, Eli Lilly, grants, Taiho Pharmaceutical, AstraZeneca, Boehringer-Ingelheim, MSD, Novartis, Sankyo Healthcare, Taiho Pharmaceutical, Merck Serono, Astellas, outside the submitted work K. Uchibori reports the employment of family member at Daiichi Sankyo. N. Yanagitani is a consultant of Chugai Pharmaceutical. R. Katayama received research funding from Chugai, TAKEDA, Toppan Printing, and Daiichi-Sankyo. N. Fujita received research grants from API corporation and Toppan Printing and consultation fees from Pfizer. All other authors declare no conflict of interest.